Examining the Incidence of Oral Human Papillomavirus (HPV) Shedding and Oral Warts After Beginning HAART in HIV-Infected Adults - NCT01029249-10011 (Clinical Trial 478177)
Permalink: http://www.ClinicalConnection.com/exp/ExpandedPatientViewStudy478177.aspx
|
** Please review additional "Nearby Studies" on right ----->
This is an archived study that is no longer available, if you
would like to find active studies please
search our studies.
|
|
 |
 |
|
| City: |
|
New York |
|
State:
|
|
NY |
| Zip Code: |
|
10011 |
| Conditions: |
|
HIV Infections |
| Purpose: |
|
Oral human papillomavirus (HPV) and oral warts are common health concerns for HIV-infected
people. This study will examine the frequency of oral HPV DNA shedding and oral warts in
HIV-infected people who are enrolled in ACTG A5257 and who are beginning treatment with
highly active antiretroviral therapy (HAART).
|
| Study summary: |
|
Oral HPV infection occurs at a higher rate among HIV-infected people than among the general
population. Recent research in the United States and Europe has also found that HIV-infected
people have a higher risk of oral and oropharyngeal squamous cell cancer than HIV-uninfected
people. In one study, it was found that HPV seropositivity was associated with an increased
risk of squamous cell carcinoma of the oropharynx (SCCOP). In addition to SCCOP, another
HPV-related health concern is oral warts, a condition for which there is no effective
treatment. Even after beginning treatment with highly active antiretroviral therapy (HAART),
active HPV replication in the mouth and oropharynx may persist in HIV-infected people,
leading to an increased risk of SCCOP and oral warts. The purpose of this study is to
evaluate the frequency of oral HPV DNA shedding and oral warts in HIV-infected people prior
to HAART initiation and at regular time points after HAART initiation.
ACTG A5257 is a study that is comparing the effectiveness of three non-nucleoside reverse
transcriptase inhibitor (NNRTI)-sparing HAART regimens in treatment-naïve participants. This
study will enroll participants from the ACTG A5257 study. Participants will attend a
baseline study visit at the same time as their ACTG A5257 baseline study visit. At baseline
and at Week 4, 16, 24, and 48 study visits, participants will undergo an examination of
their mouth, throat wash and saliva collection, and behavioral questionnaires. A blood
collection will also occur at Week 24. |
| Criteria: |
|
Inclusion Criteria:
- Meet inclusion criteria for and be enrolled in ACTG A5257
- Ability and willingness of participant or legal guardian/representative to provide
informed consent
Exclusion Criteria:
- Co-enrollment in A5260s
- Has begun receiving HAART as part of the A5257 study
- Has ever received an HPV vaccine or plans to receive an HPV vaccine in the 6 months
after study entry |
|
|
|
|
|
|
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
February 17, 2010 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical trials are medical research studies designed to test the safety and/or
effectiveness of new drugs, devices, or treatments in humans. These studies are
conducted worldwide for a range of conditions and illnesses. Learn more about
clinical research and participating in a study at
About Clinical Trials.
|
|
|
|
|